

PRESS RELEASE
WEDNESDAY, OCTOBER 14th, 2018

AD SCIENTIAM, A FRENCH STARTUP HOSTED AT THE BRAIN & SPINE INSTITUTE (PARIS), ANNOUNCES CLINICAL VALIDATION OF ITS MSCOPILOT® SOLUTION

Paris, France – Wednesday, November 14th, 2018 - MSCopilot®, Ad Scientiam's solution for monitoring patients with Multiple Sclerosis, has been clinically compared to Multiple Sclerosis Functional Composite (MSFC) standard tests.

This is the successful outcome of a 4-year R&D effort: MSCopilot® is a CE-marked, Class-I software medical device dedicated to the monitoring of patients with multiple sclerosis. It was developed in collaboration with physicians and patients and has received institutional support from Roche France.

After a successful proof-of-concept study in 30 patients in 2016, Ad Scientiam has just finalized a large multi-center study comparing the scores measured by the MSFC to those calculated by the MSCopilot® algorithms.

Conducted in 11 MS centers, this study recruited 146 patients and 76 healthy volunteers, who successively passed the standard tests on paper and then the digital tests on smartphone.

At a press conference with **Pr. Catherine Lubetzki** (Head of the Neurology department at the Pitié-Salpêtrière Hospital) and **Dr. Elisabeth Maillart** (Neurologist, Principal Investigator), Ad Scientiam confirmed that the primary endpoint and all secondary endpoints of the study had been met. MSCopilot® was found to be as sensitive and specific as the MSFC in discriminating patients from healthy volunteers, with very strong correlations between the two scores.

The performance of the MSCopilot® score was constant regardless of MS type (relapsing-remitting or progressive), age, gender or the Expanded Disability Status Scale (EDSS) score.

The acceptability of the solution was also very good. More than 80% of patients believe that MSCopilot® could improve the management of their MS and are willing to use it at home, at least once a month.

These results were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in October 2018 in Berlin and a publication is being submitted to a peer-reviewed journal.

"With just four tests, the MSCopilot® score delivers much more variables than standard tests, providing more and better data to the physicians," says **Morgane Vallée**, biostatistician at Ad Scientiam.

"New machine learning processes have been implemented to assess the validity of the score we obtained," adds **Fabien Bertillot**, Ad Scientiam's data-scientist.

Ad Scientiam's ambition is now to design a personalized digital medicine tool for monitoring and predicting the evolution of disability in patients with MS. To achieve this goal, Ad Scientiam has the support of two major partners:

- The **Brain & Spine Institute (ICM)** neuro-informatics center, through the ARAMIS research team (**Stanley Durrleman and Olivier Colliot**) and the iCONICS data management and analysis platform, developing advanced mathematical methods applied to neurosciences,
- **Microsoft France**, which will bring its expertise and solutions for storage and massive data processing.

Leveraging this increased scientific validation, Ad Scientiam will be able to accelerate the deployment of MSCopilot® in France and prepare for its international expansion.

About Ad Scientiam

Ad Scientiam develops innovative digital solutions for patient monitoring in real life. Building on the growing possibilities offered by smartphones, Ad Scientiam creates new clinically-validated medical standards, in a collaborative ecosystem of patients, doctors and researchers. MSCopilot® is Ad Scientiam's first solution CE marked as a Class 1 medical device, dedicated to the monitoring of patients with multiple sclerosis.

Ad Scientiam works on several other solutions in Alzheimer's disease, Parkinson's disease, Rheumatoid Arthritis, etc.

Ad Scientiam employs 25 people at its two sites in France (the Pitié-Salpêtrière hospital and in the Brain and Spine Institute program at STATION F) and in the United States (Seattle).

About the Brain and Spine Institute (ICM)

Founded in 2010 and located in the heart of the Pitié-Salpêtrière University Hospital, the first neurology center in France, the ICM represents a strong link between fundamental research and the clinical world. The Institute gathers more than 700 researchers and clinicians, 12 cutting-edge core facilities and 1000m² dedicated to startup incubation. Its aim is to produce ambitious research by combining scientific creativity and therapeutic purpose. Its innovative model brings together patients, doctors and researchers in a transversal approach of research that promotes collaborations and accelerates the discovery of medical innovations. Partnerships between the public and private sectors at the ICM have allowed to rapidly translate discoveries into therapeutic solutions for patients. Since 2017, the ICM is the first health partner of Station F, providing a competitive advantage in the field of connected health.

Contacts:

Ad Scientiam

Contact: info@adscientiam.com

Website: <http://www.adscientiam.com>

<http://www.mscoflight.com>

Twitter: [@adscientiam](https://twitter.com/adscientiam)

LinkedIn : Ad Scientiam

ICM

Astrid Crabouillet

astrid.crabouillet@icm-institute.org

+33 1 57 27 40 22

